logo
  

Ryanair Holdings September Traffic Increases 5% - Quick Facts

Irish low-cost airline Ryanair Holdings Plc. (RYA.L,RYAAY) said Thursday that its traffic for the month of September 2014 rose 5% to 8.5 million customers from 8.10 million customers in the same month last year.

Monthly load factor also improved 5% to 90% from 85% reported in the prior year.

Ryanair's Chief Marketing Officer, Kenny Jacobs said, "Ryanair traffic grew by 400,000 to a record 8.5m customers in September, thanks to our lower fares and our improving customer experience, including our great new website and mobile app, allocated seating, a free 2nd small carry-on bag and portable electronic devices use on all flights."

Ryanair said it continues to deliver so much more than just the lowest fares in every market for its 83.8 million customers.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Automajor General Motors plans to end production of its gasoline-powered Chevrolet Malibu car later this year as it prepares to produce new electric vehicles, reports said. Chevy Malibu, which was launched in 1964, has since been sold more than 10 million in numbers. The Malibu will end its production in November. Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast.

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
Follow RTT